Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dependent latent class partial credit models for careless and insufficient effort responding in online survey data.

Behavior research methods·2026
Same author

Planned missingness in intensive longitudinal studies: Extensions and comparisons of multiform designs.

Behavior research methods·2026
Same author

Effects of encapsulated algae oil supplements on the production of docosahexaenoic acid-enriched milk in mid-lactation dairy cows.

JDS communications·2026
Same author

Epilepsy-IEDs: An automated machine learning model for detecting interictal epileptiform discharges from scalp electroencephalograms.

iScience·2026
Same author

Bayesian evaluation for latent variable models: A tutorial on computing information criteria and bayes factors with the r package bleval.

Psychological methods·2026
Same author

A Competitive Coevolution-based Cancer Driver Pathway Identification Algorithm for Maximizing Coverage, Mutual Exclusivity, and Subnet Importance.

IEEE transactions on computational biology and bioinformatics·2026

Related Experiment Video

Updated: Jun 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Advances in Interleukin-2 Engineering and Delivery Systems for Cancer Immunotherapy.

Xiaolei Du1, Yujie Chen1, Mengchen Xu1

  • 1Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, Frontiers Science Center for New Organic Matter, Haihe Laboratory of Sustainable Chemical Transformations, College of Chemistry, Nankai University, Tianjin 300071, PR China.

ACS Applied Bio Materials
|June 24, 2026
PubMed
Summary

Interleukin-2 (IL-2) therapy shows promise for cancer treatment but faces challenges. Protein engineering and targeted delivery systems are being developed to improve IL-2

Keywords:
cancer therapydrug delivery systemsengineering modificationimmune mechanismsinterleukin-2

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Related Experiment Videos

Last Updated: Jun 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Area of Science:

  • Immunology and Cancer Immunotherapy

Background:

  • Interleukin-2 (IL-2) is a cytokine crucial for immune cell function, including regulatory T cells (Tregs), effector T cells, and natural killer (NK) cells.
  • High-dose IL-2 is an approved immunotherapy for metastatic renal cell carcinoma and melanoma, representing a significant clinical advancement.
  • Limitations of current IL-2 therapy include a short in vivo half-life, systemic toxicity, and immune suppression due to Treg activation.

Purpose of the Study:

  • To review the structural-functional relationships of IL-2 and its receptor complexes.
  • To summarize protein engineering strategies for developing improved IL-2 variants.
  • To examine IL-2 delivery systems for selective targeting of effector cells in cancer immunotherapy.

Main Methods:

  • Review of existing literature on IL-2 structure, function, and receptor interactions.
  • Analysis of protein engineering approaches to modify IL-2 properties.
  • Examination of novel IL-2 delivery systems for targeted cancer immunotherapy.

Main Results:

  • Advances in understanding IL-2 receptor subunit composition and signaling pathways.
  • Development of engineering strategies to enhance IL-2's therapeutic index.
  • Progress in mitigating IL-2-induced systemic toxicity through targeted approaches.

Conclusions:

  • Protein engineering and advanced delivery systems offer potential solutions to IL-2 therapy's limitations.
  • These strategies aim to reduce systemic toxicity and improve therapeutic efficacy in cancer treatment.
  • Further development provides a foundation for safer and more effective IL-2-based immunotherapies.